BioMelbourne Network
Progressing BioIndustry
Benitec Limited
Website Address:
http://www.benitec.com
Corporate Member:
Mr John Rawling
Company Secretary
Company Profile:
Benitec is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's core patents and licenses provide key technologies to trigger RNAi in human cells and in live animals.
The corporate goal of Benitec is to develop RNAi-based therapeutics for serious diseases such as infectious diseases, cancers and autoimmune disorders through co-investment and out licensing. Benitec's RNA-based HIV therapeutic, co-developed with the City of Hope in Duarte, California, has entered human clinical trials.
The Company's proprietary ddRNAi technology provides unique capability and significant competitive advantages for:
* Developing RNAi-based treatments for chronic life threatening diseases
* Disease modeling in vitro and in vivo.
* Target validation in vitro and in vivo.
* RNAi enabling research reagents
